…
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -4.65M | -1.70M | -6.08M | -3.40M | -5.02M |
| Net income | -4.65M | -1.93M | -6.16M | -3.48M | -5.02M |
| Selling general administrative | 5.78M | 2.79M | 6.14M | 3.47M | 0.08M |
| Selling and marketing expenses | 3.24M | 0.89M | 0.04M | 0.01M | 1.38M |
| Gross profit | -1.30M | 0.96M | 0.12M | 0.21M | -0.01M |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Ebit | -5.70M | -1.83M | -6.02M | -3.26M | -1.47M |
| Ebitda | -5.69M | -1.66M | -6.02M | -3.26M | -1.47M |
| Depreciation and amortization | 0.00M | 0.17M | 0.00M | 0.00M | 0.00M |
| Operating income | -5.70M | -1.83M | -6.02M | -3.26M | -1.47M |
| Other operating expenses | 5.81M | 3.15M | 6.16M | 3.50M | 1.67M |
| Interest expense | 0.04M | 0.06M | 0.08M | 0.08M | 0.08M |
| Net interest income | -0.03M | -0.06M | -0.08M | -0.08M | - |
| Income tax expense | -0.00M | 0.23M | 0.08M | 0.08M | 0.00M |
| Total revenue | 0.11M | 1.32M | 0.14M | 0.24M | 0.21M |
| Total operating expenses | 4.39M | 2.79M | 6.14M | 3.47M | 1.46M |
| Cost of revenue | 1.41M | 0.36M | 0.02M | 0.03M | 0.22M |
| Total other income expense net | 1.05M | 0.14M | -0.06M | -0.15M | -3.56M |
| Net income from continuing ops | -4.60M | -1.70M | -6.08M | -3.40M | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3.63M | 7.43M | 0.75M | 0.12M | 0.11M |
| Intangible assets | 0.11M | - | - | - | - |
| Other current assets | 0.32M | 0.27M | 0.04M | 0.01M | 0.02M |
| Total liab | 0.43M | 1.95M | 2.44M | 1.71M | 1.29M |
| Total stockholder equity | 3.21M | 5.48M | -1.68M | -1.59M | -1.18M |
| Other current liab | 0.26M | 0.54M | 0.61M | 0.52M | 0.13M |
| Common stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.00M | 0.00M | - |
| Retained earnings | -77.04M | -72.39M | -70.69M | -64.61M | -61.21M |
| Other assets | 0.00M | - | - | - | - |
| Cash | 0.58M | 0.16M | 0.66M | 0.08M | 0.06M |
| Total current liabilities | 0.43M | 1.95M | 2.36M | 1.57M | 1.04M |
| Current deferred revenue | - | - | 0.13M | - | - |
| Net debt | -0.58M | 0.59M | 0.19M | 0.65M | 0.77M |
| Short term debt | 0.00M | 0.75M | 0.78M | 0.58M | 0.59M |
| Short long term debt | - | 0.70M | 0.74M | 0.55M | - |
| Short long term debt total | 0.00M | 0.76M | 0.85M | 0.73M | 0.84M |
| Other stockholder equity | 80.24M | 77.82M | 69.00M | 63.02M | 60.03M |
| Total current assets | 3.43M | 7.43M | 0.75M | 0.12M | 0.11M |
| Long term investments | 0.10M | - | - | - | - |
| Short term investments | 2.37M | 6.83M | - | - | - |
| Net receivables | 0.01M | 0.00M | 0.02M | 0.01M | 0.01M |
| Long term debt | - | - | 0.02M | 0.05M | - |
| Inventory | 0.16M | 0.15M | 0.03M | 0.02M | 0.02M |
| Accounts payable | 0.16M | 0.66M | 0.84M | 0.46M | 0.32M |
| Accumulated other comprehensive income | -0.00M | 0.04M | - | - | - |
| Non currrent assets other | 0.10M | - | - | - | -0.00M |
| Non current assets total | 0.20M | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital lease obligations | 0.00M | 0.06M | 0.09M | 0.13M | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -3.56M | -6.79M | 0.00M | -0.00M | - |
| Total cash from financing activities | -0.20M | 8.51M | 1.66M | 0.88M | 0.73M |
| Net income | -4.65M | -1.70M | -6.08M | -3.40M | -5.02M |
| Change in cash | 0.42M | -0.50M | 0.58M | 0.02M | 0.05M |
| Begin period cash flow | 0.16M | 0.66M | 0.08M | 0.06M | 0.02M |
| End period cash flow | 0.58M | 0.16M | 0.66M | 0.08M | 0.06M |
| Total cash from operating activities | -3.84M | -2.22M | -1.08M | -0.86M | -0.68M |
| Issuance of capital stock | 0.00M | 8.55M | 1.43M | 0.88M | - |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | -0.01M | -0.14M | -0.01M | -0.00M | 0.01M |
| Change to account receivables | -0.00M | 0.00M | -0.01M | -0.00M | 0.01M |
| Other cashflows from financing activities | -0.20M | 8.55M | 0.24M | 0.08M | 0.70M |
| Capital expenditures | 0.11M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.77M | -0.63M | 0.52M | 0.50M | 0.29M |
| Stock based compensation | 2.41M | 0.27M | 4.48M | 1.96M | 0.56M |
| Other non cash items | -1.09M | -0.16M | 4.11M | 0.01M | 3.76M |
| Free cash flow | -3.94M | -2.22M | -1.08M | -0.86M | -0.68M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark White | Pres, CEO & Director | 1962 |
| Dr. David Owens M.D. | Chief Medical Officer & Director | 1962 |
| Mr. John Patrick Claude | Co-Founder and Director of Engineering & Devel. | NA |
| Ms. Marilyn Elson | Chief Financial Officer | 1954 |
| Mr. Joel Bradus | Director of Sales & Marketing | NA |
| Ms. Marilyn Elson | Controller | 1953 |
| Mr. Mark White | President, CEO, CFO & Director | 1962 |
| Mr. John Patrick Claude | Co-Founder and Director of Engineering & Development | NA |
| Dr. David Owens M.D. | Chief Medical Officer & Director | 1961 |
| Mr. Michael Nketiah | Senior Vice-President of Quality, Regulatory & Clinical Affairs | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.